Literature DB >> 93313

Studies on plasma inhibitors of plasma kallikrein using chromogenic peptide substrate assays.

M J Gallimore, E Amundsen, M Larsbraaten, K Lyngaas, E Fareid.   

Abstract

Mesh：

Substances：

Year:  1979        PMID： 93313     DOI： 10.1016/0049-3848(79)90213-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  6 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

2.  Contact phase of blood coagulation in cardiogenic pulmonary oedema (CPO) and adult respiratory distress syndrome (ARDS).

Authors:  C Herrera; F Velasco; A Guerrero; R Guerrero; F Alvarez; A Torres
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

3.  [Changes in the kallikrein-kinin and complement system in angiography using non-ionic contrast media].

Authors:  H M Hoffmeister; G Fuhrer; J Pirschel; W Heller
Journal:  Klin Wochenschr       Date:  1988-09-01

4.  Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.

Authors:  M Schapira; C F Scott; R W Colman
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

5.  Inactivation of kallikrein in human plasma.

Authors:  F van der Graaf; J A Koedam; B N Bouma
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

6.  Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor.

Authors:  R Guerrero; F Velasco; M Rodriguez; A Lopez; R Rojas; M A Alvarez; R Villalba; V Rubio; A Torres; D del Castillo
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.